Interview with Oleg Epstein, General Director, Materia Medica
Focus Reports first met with Materia Medica in 2006. At the time, the company was enjoying an extremely rapid pace of growth. Looking back over the last years, how has…
Address: 9 bld, 3rd Samotyochnyi per., Moscow, 127 473,Russia
Tel: +7 495 684 43 33
Web: http://www.materiamedica.ru/ru/
Research and manufacturing company Materia Medica Holding is one of the top Russian pharmaceutical companies. For more than 10 years Materia Medica Holding has been carrying out fundamental research in the pharmacology of ultra low doses and currently the company holds the leading position in this field. The researchers of the Company were the first to conduct systemic studies of ultra dilute solutions.
Company’s product portfolio includes OTC drugs of different pharmacological groups, such as immunomodulators, antiviral products and anti-inflammatory drugs(Anaferon for children, Anaferon, Ergoferon), sedative drugs, nootropics and stress – protective drugs (Tenoten, Tenoten for children), weight reduction drugs (Dietressa), regulators of the urogenital system and reproductive system functions(Afala, Impaza), the drugs for treatment of diseases of joints (Arthrofoon), and of alcohol addiction (Proproten-100). The products are marketed in Russia, the CIS countries, Europe, Asia and Latin America. The Company is constantly searching for new areas where the drugs containing ultra low doses of antibodies can be used.
The efforts of the company’s staff for development and introduction into medical practice of new highly effective remedies based on ultra low doses of antibodies to endogenous regulators were recognized with Science & Technology Award 2005 and Science & Technology Award 2006 by Government of the Russia (orders of the Government of the Russia No. 96 dd. February 20th , 2006 AND No. 12 dd. February 22nd , 2007).
The staff of Materia Medica Holding exceeds 600 people. The company has its own production site in Chelyabinsk equipped with the up-to-date GMP-compliant facilities of European manufacturers.
Materia Medica Holding actively carries on cooperation with the leading Russian and foreign research institutions aimed at conducting new studies and to obtaining clinical data.
Materia Medica Holding drugs have become known not only in Russia but also abroad. In many countries marketing authorizations for our drugs have been issued. At present the Company has expanded its activity on FSU, Europe, Asia and Latin America markets. Our affiliate company as well as our representative offices in Belarus, Uzbekistan and Kazakhstan carries out our products presentation.
We strive for developing highly efficient drugs ensuring effective treatment, prophylaxis and rehabilitation in different areas of medicine. We are sure that our drug can help millions of people to protect their health.
Currently, Materia Medica Holding manufactures more than thirty drugs and 8 of them are original products:
Anaferon — an effective drug for prevention and treatment of influenza and SARS.
Anaferon for children— the product was specially developed for treatment and prevention of influenza, SARS and other viral infections in children.
Arthrofoon — a drug for course treatment of chronic inflammatory diseases of joints (rheumatic arthritis, osteoarthritis).
Afala — a drug for treatment of prostatitis and benign prostate hyperplasia (BHP). It reduces oedema and inflammation in tissues, improves prostate functioning.
Impaza — a product for course treatment of erectile dysfunction of different etiology, increases libido and erection.
Proproten-100 — a drug used for treatment of alcoholism, reduces desire to drink and improves withdrawal symptoms. The drug efficiently eliminates the main withdrawal symptoms such as faintness, weakness, tremor, shiver, headache, irritability and insomnia.
Tenoten — it is recommended in case of acute and chronic stresses and neurosis-like conditions. It causes no drowsiness during the day, removes anxiety, and improves memory and attention.
Tenoten for children – t is recommended for children, for the treatment of Attention deficit hyperactivity disorder (ADHD).
Focus Reports first met with Materia Medica in 2006. At the time, the company was enjoying an extremely rapid pace of growth. Looking back over the last years, how has…
You founded this business in 2003, and it has since grown to encompass five offices and over 250 experts. Can you tell our readers a bit about the history behind…
The following is an interview with Dr. Smirnov, as well as Dr. Dmitri Pavlovich, Director, Clinical Operations Russia Quintiles very recently announced the launch of its first commercial project in…
The following is an interview with Dr. Pavlovich, as well as Dr. Sergey Smirnov, Director, Business Development and Operations, CEE, CIS and Russia Quintiles very recently announced the launch of…
GSK CEO Andrew Witty has said that GSK must move away from selling “white pills in Western markets” in order to offset widespread generic erosion. This means diversifying the company’s…
The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you founded Invar in 1991, and began to capitalize on foreign investment in…
Pepeliaev, Goltsblat & Partners and the major UK firm Berwin Leighton Paisner (BLP). It calls itself the first international Russian law firm. Can you explain to our readers the rationale…
You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the…
You were working for GSK since 2003 before joining Galderma this year. Some within the industry might view Galderma as a step down from the third-ranked pharmaceutical company in the…
Janssen recently signed memorandums of understanding with both the Skolkovo Foundation and ChemRar. Can you describe the strategic parameters and intended outcomes of these agreements? How do they factor into…
Mr. Demidov, you are one of the pioneers of market research studies in Russia. There is a quote you like to use: ‘Market research is a business in the United…
How would you describe CMS’s own presence in the life sciences field in Russia, and what unique competitive advantages does the firm bring to this area of practice? Over the…
With the announcement of the Pharma 2020 strategy to develop the domestic pharmaceutical industry, multinational companies have pledged an excess of $1Bn in investment into local infrastructure. Servier, however, preempted…
See our Cookie Privacy Policy Here